CO2020011027A2 - Análogos de compstatina y sus usos médicos - Google Patents

Análogos de compstatina y sus usos médicos

Info

Publication number
CO2020011027A2
CO2020011027A2 CONC2020/0011027A CO2020011027A CO2020011027A2 CO 2020011027 A2 CO2020011027 A2 CO 2020011027A2 CO 2020011027 A CO2020011027 A CO 2020011027A CO 2020011027 A2 CO2020011027 A2 CO 2020011027A2
Authority
CO
Colombia
Prior art keywords
compstatin
introduction
analogs
compstatin analogs
inhibition activity
Prior art date
Application number
CONC2020/0011027A
Other languages
English (en)
Inventor
Pernille Tofteng Shelton
Jacob Ulrik Fog
Jens Kvist Madsen
Original Assignee
Zp Spv 3 K/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zp Spv 3 K/S filed Critical Zp Spv 3 K/S
Publication of CO2020011027A2 publication Critical patent/CO2020011027A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a

Abstract

Se describen análogos de compstatina que tienen unión y actividad de inhibición del complemento mejoradas en comparación con el péptido de compstatina de 13 aminoácidos (ICVVQDWGHHRCT (C2-C12 cíclico)), en particular análogos de compstatina que adicionalmente poseen propiedades fisicoquímicas útiles, tales como aumento de solubilidad. Estos análogos incluyen variantes con un residuo de isoleucina en la posición 3 en lugar del residuo de valina de tipo natural, que proporciona péptidos de compstatina con unión y actividad de inhibición del complemento mejoradas y también permite la introducción de otras modificaciones, por ejemplo modificaciones que son capaces de aumentar la solubilidad, tal como la introducción de aminoácidos cargados o polares en la posición 9 y/o la introducción de secuencias de N- y/o C-terminales.
CONC2020/0011027A 2018-02-27 2020-09-03 Análogos de compstatina y sus usos médicos CO2020011027A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18158834 2018-02-27
EP18214949 2018-12-20
PCT/EP2019/054685 WO2019166411A1 (en) 2018-02-27 2019-02-26 Compstatin analogues and their medical uses

Publications (1)

Publication Number Publication Date
CO2020011027A2 true CO2020011027A2 (es) 2020-12-10

Family

ID=65516661

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0011027A CO2020011027A2 (es) 2018-02-27 2020-09-03 Análogos de compstatina y sus usos médicos

Country Status (17)

Country Link
US (1) US11965039B2 (es)
EP (1) EP3759120A1 (es)
JP (1) JP2021515759A (es)
KR (1) KR20200135797A (es)
CN (1) CN112041330A (es)
AU (1) AU2019228639A1 (es)
BR (1) BR112020017385A2 (es)
CA (1) CA3091993A1 (es)
CL (1) CL2020002197A1 (es)
CO (1) CO2020011027A2 (es)
IL (1) IL276877A (es)
MX (1) MX2020008902A (es)
PE (1) PE20201254A1 (es)
RU (1) RU2020128624A (es)
SG (1) SG11202008177WA (es)
TW (1) TW202000686A (es)
WO (1) WO2019166411A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019247467B2 (en) 2018-04-06 2023-01-19 The Trustees Of The University Of Pennsylvania Compstatin analogs with increased solubility and improved pharmacokinetic properties
KR20220066287A (ko) * 2019-08-27 2022-05-24 제트피 에스피브이 3 케이/에스 콤프스타틴 유사체 및 이의 의약 용도
AU2021309548A1 (en) * 2020-07-16 2023-02-23 Zp Spv 3 K/S Inhibitors of complement factor C3 and their medical uses
MX2023008330A (es) 2021-01-20 2024-01-18 Viking Therapeutics Inc Agonistas del receptor dual gip/glp-1 de molécula pequeña, composiciones farmacéuticas y preparación de las mismas para usarse en el tratamiento de trastornos metabólicos y hepáticos.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000505068A (ja) 1996-03-13 2000-04-25 トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア 補体活性化を阻害する新規ペプチド類
DE69737479T4 (de) 1996-08-30 2010-05-06 Novo Nordisk A/S Glp-1 derivate
DE69732640T2 (de) 1996-09-09 2006-01-12 Zealand Pharma A/S Festphasen-peptidsynthese
AU4648197A (en) 1997-09-17 1999-04-05 Burnham Institute, The Peptides and peptidomimetics for inhibiting complement activation
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
EP1956000B1 (en) 1999-03-17 2016-10-05 Novo Nordisk A/S Acylating agents useful for acylating peptides
AU2003275075A1 (en) 2002-09-20 2004-04-08 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved activity
CN105582523B (zh) 2005-10-08 2022-04-15 阿佩利斯制药公司 用于眼部病症的补体抑制素和其类似物
CA2971349C (en) 2005-11-28 2020-09-08 The Trustees Of The University Of Pennsylvania Potent compstatin analogs
US8442776B2 (en) 2007-06-08 2013-05-14 The Trustees Of The University Of Pennsylvania Structure of compstatin-C3 complex and use for rational drug design
US8946145B2 (en) * 2009-05-01 2015-02-03 The Trustees Of The University Of Pennsylvania Modified compstatin with peptide backbone and C-terminal modifications
CA2813049A1 (en) 2010-09-23 2012-03-29 The Trustees Of The University Of Pennsylvania Modified compstatin with improved stability and binding properties
DK2753636T3 (da) * 2011-09-07 2020-02-03 Univ Pennsylvania Compstatinanaloger med forbedret farmakokinetiske egenskaber
US20160194359A1 (en) 2012-11-15 2016-07-07 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
WO2014100407A1 (en) 2012-12-19 2014-06-26 The Regents Of The University Of California Compstatin analogs
KR20220066287A (ko) * 2019-08-27 2022-05-24 제트피 에스피브이 3 케이/에스 콤프스타틴 유사체 및 이의 의약 용도

Also Published As

Publication number Publication date
AU2019228639A1 (en) 2020-09-17
WO2019166411A1 (en) 2019-09-06
CA3091993A1 (en) 2019-09-06
RU2020128624A (ru) 2022-03-28
EP3759120A1 (en) 2021-01-06
BR112020017385A2 (pt) 2020-12-15
US20230192770A1 (en) 2023-06-22
SG11202008177WA (en) 2020-09-29
IL276877A (en) 2020-10-29
MX2020008902A (es) 2020-12-03
KR20200135797A (ko) 2020-12-03
US11965039B2 (en) 2024-04-23
TW202000686A (zh) 2020-01-01
CN112041330A (zh) 2020-12-04
CL2020002197A1 (es) 2021-03-05
PE20201254A1 (es) 2020-11-16
JP2021515759A (ja) 2021-06-24

Similar Documents

Publication Publication Date Title
CO2020011027A2 (es) Análogos de compstatina y sus usos médicos
ECSP15042898A (es) Péptidos y composiciones para el tratamiento de daño articular
CL2017002345A1 (es) Un nuevo complejo que comprende un péptido de penetración celular, una molécula cargo y un agonista peptídico de tlr
CO2022003556A2 (es) Análogos de compstatina y sus usos médicos
PE20190335A1 (es) Receptores de celulas t
JOP20200055A1 (ar) مركبات بيرازولو بيريميدينون واستخداماتها
EA201691111A1 (ru) Химерные белки фактора viii и их применение
CL2018000215A1 (es) Uso de variantes de péptido natriuretico de tipo c para tratar displasia esquelética.
CO2018005306A2 (es) Variantes del factor viii reducido con cpg, composiciones y métodos y usos para el tratamiento de trastornos de la hemostasia
EA201890640A1 (ru) Рекомбинантные векторы, содержащие пептид 2а
PE20130041A1 (es) Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23)
PE20160243A1 (es) Polipeptido para la escision hidrolitica de la zearalenona y/o derivados de la zearalenona, polinucleotido aislado de la misma y polieptido que contiene aditivo, uso y procedimiento de los mismos
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
DOP2017000287A (es) Analogos glp-1 lipidados resistentes a proteasa
CO2019009080A2 (es) Péptidos y métodos para el tratamiento de diabetes
AR078445A1 (es) Agonistas del peptido natriuretico tipo b (npr -b)
AR100310A1 (es) Moléculas para transporte de antígeno modular mejoradas y sus usos
CL2018002113A1 (es) Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipo de cancer (divisonal solicitud 201800545)
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
AR095386A1 (es) Péptidos de kntc2 y vacunas que los contienen
BR112017014737A2 (pt) formulação de peptídeos inibidores de mk2
BR112018072968A2 (pt) peptídeos monolipidados resistentes às proteases
PE20210185A1 (es) Apirasas solubilizadas, metodos y usos
MX2020010520A (es) Analogos de compstatina con mayor solubilidad y mejores propiedades farmacocineticas.